$MBIO
MUSTANG BIO, INC.

2021 Form 10-K Financial Statement

#000155837022004143 Filed on March 23, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.02M $2.410M $9.510M
YoY Change 15.85% 17.56% -0.63%
% of Gross Profit
Research & Development $49.86M $17.83M $37.24M
YoY Change 33.91% 28.55% 23.95%
% of Gross Profit
Depreciation & Amortization $2.200M $460.0K $1.700M
YoY Change 29.41% 31.43% 30.77%
% of Gross Profit
Operating Expenses $66.72M $20.74M $56.81M
YoY Change 17.46% 30.28% 23.8%
Operating Profit -$66.72M -$56.81M
YoY Change 17.46% 23.8%
Interest Expense $353.0K $130.0K -$3.210M
YoY Change -111.0% -144.83% 542.0%
% of Operating Profit
Other Income/Expense, Net $353.0K -$3.209M
YoY Change -111.0% 536.71%
Pretax Income -$66.37M -$20.61M -$60.02M
YoY Change 10.58% 27.14% 29.38%
Income Tax
% Of Pretax Income
Net Earnings -$66.37M -$20.61M -$60.02M
YoY Change 10.59% 27.14% 29.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.76
Diluted Earnings Per Share -$755.2K -$312.2K -$1.141M
COMMON SHARES
Basic Shares Outstanding 87.89M
Diluted Shares Outstanding 87.89M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.6M $97.80M $97.80M
YoY Change 12.08% 59.28% 59.28%
Cash & Equivalents $109.6M $97.80M $97.80M
Short-Term Investments
Other Short-Term Assets $2.038M $1.700M $1.700M
YoY Change 19.88% 6.25% 6.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $111.7M $99.53M $99.50M
YoY Change 12.27% 57.83% 57.69%
LONG-TERM ASSETS
Property, Plant & Equipment $12.10M $8.028M $9.100M
YoY Change 32.99% 1.16% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.362M $250.0K $1.300M
YoY Change 4.77% 0.0% 0.0%
Total Long-Term Assets $13.46M $10.37M $10.40M
YoY Change 29.46% -0.15% 0.97%
TOTAL ASSETS
Total Short-Term Assets $111.7M $99.53M $99.50M
Total Long-Term Assets $13.46M $10.37M $10.40M
Total Assets $125.2M $109.9M $109.9M
YoY Change 13.89% 49.64% 49.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.512M $3.518M $3.500M
YoY Change 0.34% 87.43% 84.21%
Accrued Expenses $6.749M $5.100M $5.100M
YoY Change 32.33% 1600.0% 45.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $10.82M $9.515M $9.500M
YoY Change 13.84% 22.44% 21.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $1.955M $2.000M $2.000M
YoY Change -2.25% 11.11% 11.11%
Total Long-Term Liabilities $1.955M $2.000M $2.000M
YoY Change -2.25% -85.71% -85.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.82M $9.515M $9.500M
Total Long-Term Liabilities $1.955M $2.000M $2.000M
Total Liabilities $12.77M $11.47M $11.50M
YoY Change 11.04% -47.39% -47.25%
SHAREHOLDERS EQUITY
Retained Earnings -$185.5M
YoY Change 47.84%
Common Stock $276.0M
YoY Change 60.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $112.4M $98.44M $98.40M
YoY Change
Total Liabilities & Shareholders Equity $125.2M $109.9M $109.9M
YoY Change 13.89% 49.64% 49.73%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$66.37M -$20.61M -$60.02M
YoY Change 10.59% 27.14% 29.37%
Depreciation, Depletion And Amortization $2.200M $460.0K $1.700M
YoY Change 29.41% 31.43% 30.77%
Cash From Operating Activities -$53.67M -$9.480M -$37.32M
YoY Change 43.81% -0.11% 11.13%
INVESTING ACTIVITIES
Capital Expenditures $3.986M -$700.0K $1.925M
YoY Change 107.06% -22.22% -17.91%
Acquisitions
YoY Change
Other Investing Activities -$1.380M -$770.0K -$2.490M
YoY Change -44.58% 54.0% -115.32%
Cash From Investing Activities -$5.366M -$1.460M -$4.412M
YoY Change 21.62% 5.04% -131.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $37.23M
YoY Change -100.0% 17.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.85M 33.49M 78.12M
YoY Change -9.31% 19.97%
NET CHANGE
Cash From Operating Activities -53.67M -9.480M -37.32M
Cash From Investing Activities -5.366M -1.460M -4.412M
Cash From Financing Activities 70.85M 33.49M 78.12M
Net Change In Cash 11.81M 22.55M 36.39M
YoY Change -67.54% -307.26% -19.92%
FREE CASH FLOW
Cash From Operating Activities -$53.67M -$9.480M -$37.32M
Capital Expenditures $3.986M -$700.0K $1.925M
Free Cash Flow -$57.65M -$8.780M -$39.24M
YoY Change 46.91% 2.21% 9.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2021Q2 dei Entity Public Float
EntityPublicFloat
0
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001680048
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Tax Credit Carryforward Expiration Date
TaxCreditCarryforwardExpirationDate
2033-12-31
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38191
CY2021 dei Entity Registrant Name
EntityRegistrantName
MUSTANG BIO, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3828760
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
377 Plantation Street
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Worcester
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01605
CY2021 dei City Area Code
CityAreaCode
781
CY2021 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
MBIO
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
New York, NY
CY2021 dei Auditor Firm
AuditorFirmId
185
CY2020 dei Auditor Name
AuditorName
BDO USA, LLP
CY2020 dei Auditor Location
AuditorLocation
Boston, MA
CY2020 dei Auditor Firm
AuditorFirmId
243
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109618000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97804000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
50000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
15000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2038000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1715000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
111706000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
99534000
CY2021Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
9025000
CY2020Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
7529000
CY2021Q4 mbio Construction In Process Net
ConstructionInProcessNet
2027000
CY2020Q4 mbio Construction In Process Net
ConstructionInProcessNet
499000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
362000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1050000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1088000
CY2021Q4 us-gaap Assets
Assets
125170000
CY2020Q4 us-gaap Assets
Assets
109900000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9744000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8747000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
723000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
490000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
348000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
278000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10815000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9515000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
270000
CY2020Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1685000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1950000
CY2021Q4 us-gaap Liabilities
Liabilities
12770000
CY2020Q4 us-gaap Liabilities
Liabilities
11465000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
2536607
CY2020Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
2103122
CY2021Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
4329000
CY2020Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
7939000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
359906000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
275963000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251844000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185474000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
112400000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
98435000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125170000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109900000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
49864000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
37237000
CY2021 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
5842000
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
10064000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11017000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9505000
CY2021 us-gaap Operating Expenses
OperatingExpenses
66723000
CY2020 us-gaap Operating Expenses
OperatingExpenses
56806000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-66723000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-56806000
CY2020 mbio Offering Costs For Issuance Of Common Shares At Market Offering In Accounts Payable And Accrued Expenses
OfferingCostsForIssuanceOfCommonSharesAtMarketOfferingInAccountsPayableAndAccruedExpenses
84000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
368000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
708000
CY2021 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
15000
CY2020 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3917000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
353000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3209000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-66370000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-60015000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87885235
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52588781
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51652000
CY2020 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
7577000
CY2020 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
58597000
CY2020 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
1514000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34842000
CY2020 mbio Stock Issued During Period Value New Issues Equity Fee On Public Offering
StockIssuedDuringPeriodValueNewIssuesEquityFeeOnPublicOffering
932000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
349000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2987000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-60015000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
98435000
CY2021 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
4212000
CY2021 mbio Stock Issued During Period Value At Marketing Offering
StockIssuedDuringPeriodValueAtMarketingOffering
70622000
CY2021 mbio Stock Issued During Period Value Equity Fee On At Market Offering
StockIssuedDuringPeriodValueEquityFeeOnAtMarketOffering
1884000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
309000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3308000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-66370000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
112400000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-66370000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-60015000
CY2021 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
1884000
CY2020 mbio Issuance Of Common Shares Equity Fee On At Market Offering
IssuanceOfCommonSharesEquityFeeOnAtMarketOffering
1514000
CY2021 mbio Issuance Of Common Shares Equity Fee On Public Offering
IssuanceOfCommonSharesEquityFeeOnPublicOffering
0
CY2020 mbio Issuance Of Common Shares Equity Fee On Public Offering
IssuanceOfCommonSharesEquityFeeOnPublicOffering
932000
CY2021 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
4212000
CY2020 mbio Adjustment To Recognize Effect Of Research And Development Expense Attributable To Asset Acquired Via Stock Issuance
AdjustmentToRecognizeEffectOfResearchAndDevelopmentExpenseAttributableToAssetAcquiredViaStockIssuance
7577000
CY2021 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
1630000
CY2020 mbio Research And Development License In Accounts Payable And Accrued Expense
ResearchAndDevelopmentLicenseInAccountsPayableAndAccruedExpense
2487000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3308000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2987000
CY2021 us-gaap Depreciation
Depreciation
2167000
CY2020 us-gaap Depreciation
Depreciation
1677000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2321000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
139000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
108000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
401000
CY2021 mbio Offering Costs For Issuance Of Common Shares At Market Offering In Accounts Payable And Accrued Expenses
OfferingCostsForIssuanceOfCommonSharesAtMarketOfferingInAccountsPayableAndAccruedExpenses
0
CY2017Q4 mbio Lessee Operating Lease Total Abatements Over Lease Term
LesseeOperatingLeaseTotalAbatementsOverLeaseTerm
600000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
84000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
35000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-4000
CY2021 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
-408000
CY2020 mbio Increase Decrease In Accounts Payable And Accrued Expenses Excluding Amounts Due To Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesExcludingAmountsDueToRelatedParties
3151000
CY2021 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
233000
CY2020 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-106000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
270000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2021 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
296000
CY2020 mbio Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-128000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53667000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37319000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1380000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2487000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3986000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1925000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5366000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4412000
CY2021 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
71919000
CY2020 mbio Proceeds From Issuance Of Common Shares At Market Offering
ProceedsFromIssuanceOfCommonSharesAtMarketOffering
59805000
CY2021 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
1381000
CY2020 mbio Offering Costs For Issuance Of Common Shares At Market Offering
OfferingCostsForIssuanceOfCommonSharesAtMarketOffering
1124000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37230000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2388000
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0
CY2020 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
15750000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
309000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
349000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70847000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
78122000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
11814000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
36391000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98804000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62413000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110618000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98804000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1593000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1270000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000
CY2021 us-gaap Stock Issued1
StockIssued1
7577000
CY2020 us-gaap Stock Issued1
StockIssued1
4923000
CY2021 mbio Research And Development Licenses Expenditure Incurred But Not Yet Paid
ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid
250000
CY2020 mbio Research And Development Licenses Expenditure Incurred But Not Yet Paid
ResearchAndDevelopmentLicensesExpenditureIncurredButNotYetPaid
0
CY2021 mbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
101000
CY2020 mbio Lease Liabilities Arising From Obtaining Right Of Use Assets
LeaseLiabilitiesArisingFromObtainingRightOfUseAssets
0
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251800000
CY2021 mbio Number Of Subsidiaries
NumberOfSubsidiaries
0
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000.0
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1000000.0
CY2021 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7316869
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8565018
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
0
CY2016Q3 mbio Preferred Stock Voting Rights Multiplier
PreferredStockVotingRightsMultiplier
1.1
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16786000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11595000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5734000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3567000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11052000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8028000
CY2021 us-gaap Depreciation
Depreciation
2200000
CY2020 us-gaap Depreciation
Depreciation
1700000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3512000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3518000
CY2021Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
3083000
CY2020Q4 mbio Research And Development Current
ResearchAndDevelopmentCurrent
2862000
CY2021Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
2595000
CY2020Q4 mbio Accrued Compensation Current
AccruedCompensationCurrent
2009000
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
554000
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
358000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9744000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8747000
CY2017Q4 us-gaap Net Rentable Area
NetRentableArea
27043
CY2017Q4 mbio Lessee Operating Lease Total Base Rent Net Of Abatements
LesseeOperatingLeaseTotalBaseRentNetOfAbatements
3600000
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
800000
CY2017Q4 mbio Lessee Security Deposit Upon Full Occupancy
LesseeSecurityDepositUponFullOccupancy
1300000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1100000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2200000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1100000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
315000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
330000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
599000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
470000
CY2021 us-gaap Lease Cost
LeaseCost
914000
CY2020 us-gaap Lease Cost
LeaseCost
800000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
484000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
76000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
516000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
529000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
513000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
516000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
439000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2513000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
481000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2033000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
25000000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
150000000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
150000000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3308000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2987000
CY2021 mbio Employee Stock Purchase Plan Predetermined Offering Period Lower Fair Market Value Percentage
EmployeeStockPurchasePlanPredeterminedOfferingPeriodLowerFairMarketValuePercentage
0.85
CY2021 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
255177
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
744823
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.16
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.16
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.05
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.04
CY2021 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
0
CY2020 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatePercent
0
CY2021 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
0
CY2020 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatePercent
0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.41
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.41
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
66879000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45090000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2702000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2444000
CY2021Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
59000
CY2020Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
59000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
13977000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
12804000
CY2021Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
755000
CY2020Q4 mbio Deferred Tax Asset Operating Lease Liabilities
DeferredTaxAssetOperatingLeaseLiabilities
825000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1035000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
504000
CY2021Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
6000
CY2020Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
7000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9728000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
5743000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95141000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
67476000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94751000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67073000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
390000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
403000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
390000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
403000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
94800000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
67100000
CY2021 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001558370-22-004143-index-headers.html Edgar Link pending
0001558370-22-004143-index.html Edgar Link pending
0001558370-22-004143.txt Edgar Link pending
0001558370-22-004143-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20211231.xsd Edgar Link pending
tmb-20211231x10k.htm Edgar Link pending
tmb-20211231x10k_htm.xml Edgar Link completed
tmb-20211231xex23d1.htm Edgar Link pending
tmb-20211231xex23d2.htm Edgar Link pending
tmb-20211231xex31d1.htm Edgar Link pending
tmb-20211231xex31d2.htm Edgar Link pending
tmb-20211231xex32d1.htm Edgar Link pending
tmb-20211231xex32d2.htm Edgar Link pending
tmb-20211231xex4d3.htm Edgar Link pending
tmb-20211231_cal.xml Edgar Link unprocessable
tmb-20211231_def.xml Edgar Link unprocessable
tmb-20211231_lab.xml Edgar Link unprocessable
tmb-20211231_pre.xml Edgar Link unprocessable